Roivant receives bad news — and so does Softbank

 Last month, Softbank, through its massive Vision Fund, led the single biggest private financing round for a health care company ever —  funneling $1.1 billion into the drug holding outfit Roivant Sciences. Today, the Japanese conglomerate might be regretting that decision. The reason: despite hundreds of millions of dollars poured into one of Roivant’s publicly traded… Read More

Responses are currently closed, but you can trackback from your own site.

Comments are closed.